Summary

The global Antibody-drug Conjugates market is projected to grow from US$ 15480 million in 2025 to US$ 39213 million by 2032, at a CAGR of 14.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Antibody-drug Conjugates are targeted biopharmaceuticals that combine a monoclonal antibody with a cytotoxic or biologically active payload through a chemical linker. The antibody recognizes a tumor-associated antigen, enabling selective internalization or localized payload release while reducing systemic exposure relative to conventional chemotherapy. Core product attributes include antigen specificity, antibody format, linker stability and cleavage mechanism, payload class and potency, drug-to-antibody ratio, conjugation-site distribution, aggregation level, formulation stability and dosing strength. Commercial products are primarily supplied as intravenous liquid or lyophilized injections for solid tumors and hematologic malignancies. This study focuses on commercial Antibody-drug Conjugates and evaluates the market by payload mechanism, linker type, conjugation technology, target antigen, therapeutic indication and geographic market. Market value is measured primarily through manufacturer-recognized net product sales because vial strengths, body-weight-based dosing, treatment cycles, regional reimbursement and alliance accounting differ materially between products.
Key Findings
Global Antibody-drug Conjugate shipments reached approximately 6.0 million standard vial equivalents in 2025
The weighted average manufacturer selling price was approximately USD 2,580 per standard vial equivalent in 2025
More than 15 Antibody-drug Conjugates had entered commercial use across major markets by 2025
North America remains the largest regional market supported by rapid launch uptake and premium oncology reimbursement
Solid tumors have become the principal demand base while hematologic malignancies retain established clinical positions
Topoisomerase I inhibitor payloads and cleavable linkers are driving the fastest product expansion
Market Trends
Antibody-drug Conjugates are evolving from relatively heterogeneous first-generation products toward more stable, homogeneous and therapeutically differentiated platforms. Development priorities are shifting from late-line hematologic indications to larger solid-tumor populations, earlier treatment lines and biomarker-defined pan-tumor opportunities. New products increasingly use highly potent topoisomerase I inhibitors, optimized cleavable linkers and controlled drug-to-antibody ratios to strengthen bystander activity while managing systemic toxicity. Site-specific conjugation, biparatopic or bispecific antibodies, dual-payload architectures and immune-stimulating payloads represent the next layer of product innovation, although their manufacturing and regulatory requirements remain demanding. At the clinical level, combination regimens with immune checkpoint inhibitors and other targeted therapies are expanding the addressable population. Companion diagnostics, quantitative antigen testing and resistance monitoring are consequently becoming more important to patient selection, treatment sequencing and lifecycle management.
Market Dynamics
Drivers
Market expansion is being driven by the broadening of approved indications, movement into earlier treatment lines and continued validation of ADCs in major solid tumors. Successful products have demonstrated that an effective antibody, linker and payload combination can improve clinical outcomes in patients with limited alternatives, supporting physician adoption and premium oncology pricing. Pharmaceutical companies are increasing internal development, licensing and co-development investment because a validated ADC platform can generate multiple target-specific candidates. Growth is also reinforced by improved biomarker testing, expansion of oncology treatment infrastructure and increasing regulatory acceptance of ADCs across North America, Europe and Asia.
Restraints
ADC development and production involve substantially greater complexity than conventional monoclonal antibodies. Manufacturers must coordinate antibody production, high-potency payload synthesis, linker chemistry, conjugation, purification, aseptic filling and specialized analytical testing under tightly controlled conditions. Payload containment requirements, limited qualified capacity, long production lead times and low initial batch volumes increase unit costs. Commercial adoption may also be constrained by treatment-related toxicities, dose interruptions, regional reimbursement negotiations and the need for specialized infusion and adverse-event management. These factors can delay penetration even after regulatory approval.
Opportunities
The most attractive opportunities are emerging from new tumor targets, improved therapeutic windows and expansion beyond heavily pretreated patients. Targets such as B7-H3, HER3, CLDN18.2, c-MET and other tumor-associated antigens offer room for differentiated products, particularly where existing therapies provide limited durability. Further opportunities exist in earlier-stage disease, perioperative treatment, biomarker-defined pan-tumor indications and rational combinations with immunotherapy. Asia-Pacific offers additional potential through local clinical development, regional licensing, domestic manufacturing and broader reimbursement access. Platform suppliers and specialized contract manufacturers can also benefit as developers seek external capacity for payload production, conjugation and high-potency fill-finish operations.
Challenges
The principal challenge is maintaining a sufficiently wide therapeutic index while preserving strong antitumor activity. Antigen heterogeneity, variable internalization, payload resistance, linker instability and off-target toxicity can weaken clinical differentiation or limit dose intensity. Developers must also demonstrate superiority against rapidly changing standards of care, requiring larger and more expensive comparative trials. Intellectual-property overlap across antibodies, linkers, payloads and conjugation methods increases freedom-to-operate risk. Commercially, companies face indication crowding, pricing scrutiny and the possibility that competing ADCs, bispecific antibodies, radioligand therapies or other targeted modalities will reduce the value of late-entry products.
Industry Chain Analysis
The upstream ADC industry chain comprises monoclonal antibody cell lines and biologic drug substance, linker intermediates, highly potent payloads, conjugation reagents, chromatography resins, single-use processing systems and analytical materials. Payload and linker production require advanced organic synthesis, containment and impurity control, while antibody production relies on mature mammalian-cell bioprocessing. Midstream activities integrate antibody manufacture with conjugation, purification, formulation, sterile filling, quality testing and cold-chain release. Process consistency is critical because changes in drug-to-antibody ratio, free payload, aggregation or conjugation-site distribution can materially affect efficacy, safety and shelf life.
Value creation is concentrated in target validation, proprietary linker-payload chemistry, reproducible conjugation, clinical differentiation, regulatory execution and commercial access. Downstream products are distributed through oncology hospitals, specialist treatment centers, authorized pharmaceutical distributors and specialty channels, with payment influenced by indication, patient weight, treatment cycle, vial strength, reimbursement and negotiated discounts. Commercial ADCs can support high product-level gross margins, but development failures, pharmacovigilance, diagnostic support and post-approval trials consume substantial lifecycle investment. Supply reliability and capacity planning therefore remain important competitive factors alongside clinical performance.
Segment Insights
By payload mechanism, microtubule inhibitors retain a substantial installed commercial base through established products, while topoisomerase I inhibitors are gaining strategic importance because of their activity in solid tumors and potential bystander effect. DNA-damaging payloads remain important in selected hematologic indications but represent a narrower commercial segment. Cleavable linkers increasingly dominate newer product development because they facilitate intracellular or tumor-microenvironment payload release, whereas non-cleavable linkers retain relevance where plasma stability and controlled intracellular processing are prioritized.
Conventional stochastic conjugation remains widely used in marketed products because of established manufacturing experience and regulatory familiarity. However, site-specific and controlled conjugation technologies are attracting greater development investment because they can narrow drug-to-antibody ratio distribution and improve batch consistency. Solid tumors represent the largest application segment, led by breast, urothelial, lung, gynecologic and gastrointestinal cancers. Hematologic malignancies remain an important established segment, especially where validated lineage antigens support efficient internalization and clear patient selection.
Downstream Market Opportunities
The largest downstream opportunity lies in expanding ADCs from salvage therapy into earlier treatment lines and curative-intent settings. Breast cancer remains a major commercial foundation, while urothelial, lung, ovarian, cervical, gastric and other biomarker-defined solid tumors are creating additional demand. Treatment centers increasingly require integrated diagnostic testing, standardized toxicity-management pathways and dependable product availability rather than drug supply alone. Opportunities are also emerging from community oncology adoption, combination regimens and broader testing of low or heterogeneous antigen expression. Products that demonstrate clinically meaningful survival benefits, manageable adverse events and practical dosing schedules are better positioned to secure formulary access and sustained physician use.
Regional Insights
North America remains the largest Antibody-drug Conjugates market because the United States combines early regulatory launches, concentrated oncology expertise, broad biomarker testing and relatively high net drug prices. Commercial uptake can be rapid when an ADC receives a differentiated label or moves into an earlier treatment line, although payer controls and indication-specific reimbursement are becoming more influential. Europe represents a major but more price-controlled market, with country-level health technology assessment, reimbursement timing and treatment guidelines producing uneven launch curves.
Asia-Pacific is developing into the most dynamic regional opportunity. Japan combines established ADC innovation with advanced oncology infrastructure, while China is expanding domestic development, manufacturing capacity, regulatory approvals and commercial partnerships. Chinese products are also increasing licensing activity in international markets, strengthening the region’s role in global innovation rather than only local supply. Other emerging markets offer longer-term demand potential, but access remains constrained by oncology budgets, diagnostic availability, specialist capacity and cold-chain distribution.
Competitive Landscape Analysis
Competition is shifting from a small group of early ADC pioneers toward integrated global pharmaceutical portfolios and specialized platform companies. Daiichi Sankyo and AstraZeneca have established a strong position around the DXd platform, while Roche retains an important commercial franchise across solid tumors and hematologic malignancies. Pfizer’s acquisition of Seagen consolidated Padcev, Adcetris and Tivdak within a larger oncology organization, and AbbVie’s acquisition of ImmunoGen brought Elahere and related technology into its portfolio. Gilead, Astellas, GSK, Takeda and ADC Therapeutics compete through marketed products, partnerships or indication expansion. In China, RemeGen and Kelun-Biotech have entered commercial-stage competition, while Hengrui, Hansoh, CSPC, Mabwell, Duality Biologics, MediLink Therapeutics and other developers are advancing differentiated targets and linker-payload platforms. Future leadership will depend less on the number of pipeline candidates and more on clinical differentiation, manufacturing reproducibility, biomarker strategy, global regulatory execution, market access and the ability to manage combination development across multiple indications.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Antibody-drug Conjugates market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Daiichi Sankyo Company, Limited
Roche
Pfizer Inc.
Gilead Sciences, Inc.
Astellas Pharma Inc.
AbbVie Inc.
GSK plc
ADC Therapeutics SA
Takeda Pharmaceutical Company Limited
AstraZeneca plc
Genmab A/S
Johnson & Johnson
Merck & Co., Inc.
MacroGenics, Inc.
Sutro Biopharma, Inc.
Heidelberg Pharma AG
RemeGen Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Innovent Biologics, Inc.
CSPC Pharmaceutical Group Limited
Mabwell (Shanghai) Bioscience Co., Ltd.
Lepu Biopharma Co., Ltd.
Duality Biologics (Shanghai) Co., Ltd.
MediLink Therapeutics (Suzhou) Co., Ltd.
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Hangzhou DAC Biotechnology Co., Ltd.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
Sichuan Biokin Pharmaceutical Co., Ltd.
Bio-Thera Solutions, Ltd.
Segment by Type
HER2-Directed ADCs
TROP2-Directed ADCs
Hematologic-Lineage Antigen ADCs
Other Target Antigen ADCs
Segment by Payload Mechanism
Topoisomerase I Inhibitor ADCs
Microtubule Inhibitor ADCs
DNA-Damaging ADCs
Other Payload ADCs
Segment by Drug-To-Antibody Ratio
DAR Up To 4
DAR Above 4 And Below 8
DAR 8 And Above
Other
Segment by Application
Breast and Gynecologic Malignancies
Lung and Other Thoracic Malignancies
Other Solid Tumors
Hematologic Malignancies
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Antibody-drug Conjugates study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Antibody-drug Conjugates: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Antibody-drug Conjugates Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 HER2-Directed ADCs
1.2.3 TROP2-Directed ADCs
1.2.4 Hematologic-Lineage Antigen ADCs
1.2.5 Other Target Antigen ADCs
1.3 Market Segmentation by Payload Mechanism
1.3.1 Global Antibody-drug Conjugates Market Size by Payload Mechanism, 2021 vs 2025 vs 2032
1.3.2 Topoisomerase I Inhibitor ADCs
1.3.3 Microtubule Inhibitor ADCs
1.3.4 DNA-Damaging ADCs
1.3.5 Other Payload ADCs
1.4 Market Segmentation by Drug-To-Antibody Ratio
1.4.1 Global Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio, 2021 vs 2025 vs 2032
1.4.2 DAR Up To 4
1.4.3 DAR Above 4 And Below 8
1.4.4 DAR 8 And Above
1.4.5 Other
1.5 Market Segmentation by Application
1.5.1 Global Antibody-drug Conjugates Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Breast and Gynecologic Malignancies
1.5.3 Lung and Other Thoracic Malignancies
1.5.4 Other Solid Tumors
1.5.5 Hematologic Malignancies
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Antibody-drug Conjugates Revenue Estimates and Forecasts (2021-2032)
2.2 Global Antibody-drug Conjugates Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Antibody-drug Conjugates Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Antibody-drug Conjugates Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 HER2-Directed ADCs: Market Share by Key Players
3.3.2 TROP2-Directed ADCs: Market Share by Key Players
3.3.3 Hematologic-Lineage Antigen ADCs: Market Share by Key Players
3.3.4 Other Target Antigen ADCs: Market Share by Key Players
3.4 Global Antibody-drug Conjugates Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Antibody-drug Conjugates Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Antibody-drug Conjugates Market by Payload Mechanism
4.2.1 Global Revenue by Payload Mechanism (2021-2032)
4.2.2 Global Revenue-Based Market Share by Payload Mechanism (2021-2032)
4.3 Global Antibody-drug Conjugates Market by Drug-To-Antibody Ratio
4.3.1 Global Revenue by Drug-To-Antibody Ratio (2021-2032)
4.3.2 Global Revenue-Based Market Share by Drug-To-Antibody Ratio (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Antibody-drug Conjugates Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Antibody-drug Conjugates Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Antibody-drug Conjugates Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Antibody-drug Conjugates Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Antibody-drug Conjugates Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Antibody-drug Conjugates Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Antibody-drug Conjugates Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Antibody-drug Conjugates Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Antibody-drug Conjugates Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Antibody-drug Conjugates Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Antibody-drug Conjugates Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Corporation Information
11.1.2 Daiichi Sankyo Company, Limited Business Overview
11.1.3 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product Features and Attributes
11.1.4 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.1.5 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue by Product in 2025
11.1.6 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue by Application in 2025
11.1.7 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue by Geographic Area in 2025
11.1.8 Daiichi Sankyo Company, Limited Antibody-drug Conjugates SWOT Analysis
11.1.9 Daiichi Sankyo Company, Limited Recent Developments
11.2 Roche
11.2.1 Roche Corporation Information
11.2.2 Roche Business Overview
11.2.3 Roche Antibody-drug Conjugates Product Features and Attributes
11.2.4 Roche Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.2.5 Roche Antibody-drug Conjugates Revenue by Product in 2025
11.2.6 Roche Antibody-drug Conjugates Revenue by Application in 2025
11.2.7 Roche Antibody-drug Conjugates Revenue by Geographic Area in 2025
11.2.8 Roche Antibody-drug Conjugates SWOT Analysis
11.2.9 Roche Recent Developments
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Corporation Information
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Antibody-drug Conjugates Product Features and Attributes
11.3.4 Pfizer Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.3.5 Pfizer Inc. Antibody-drug Conjugates Revenue by Product in 2025
11.3.6 Pfizer Inc. Antibody-drug Conjugates Revenue by Application in 2025
11.3.7 Pfizer Inc. Antibody-drug Conjugates Revenue by Geographic Area in 2025
11.3.8 Pfizer Inc. Antibody-drug Conjugates SWOT Analysis
11.3.9 Pfizer Inc. Recent Developments
11.4 Gilead Sciences, Inc.
11.4.1 Gilead Sciences, Inc. Corporation Information
11.4.2 Gilead Sciences, Inc. Business Overview
11.4.3 Gilead Sciences, Inc. Antibody-drug Conjugates Product Features and Attributes
11.4.4 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.4.5 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue by Product in 2025
11.4.6 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue by Application in 2025
11.4.7 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue by Geographic Area in 2025
11.4.8 Gilead Sciences, Inc. Antibody-drug Conjugates SWOT Analysis
11.4.9 Gilead Sciences, Inc. Recent Developments
11.5 Astellas Pharma Inc.
11.5.1 Astellas Pharma Inc. Corporation Information
11.5.2 Astellas Pharma Inc. Business Overview
11.5.3 Astellas Pharma Inc. Antibody-drug Conjugates Product Features and Attributes
11.5.4 Astellas Pharma Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.5.5 Astellas Pharma Inc. Antibody-drug Conjugates Revenue by Product in 2025
11.5.6 Astellas Pharma Inc. Antibody-drug Conjugates Revenue by Application in 2025
11.5.7 Astellas Pharma Inc. Antibody-drug Conjugates Revenue by Geographic Area in 2025
11.5.8 Astellas Pharma Inc. Antibody-drug Conjugates SWOT Analysis
11.5.9 Astellas Pharma Inc. Recent Developments
11.6 AbbVie Inc.
11.6.1 AbbVie Inc. Corporation Information
11.6.2 AbbVie Inc. Business Overview
11.6.3 AbbVie Inc. Antibody-drug Conjugates Product Features and Attributes
11.6.4 AbbVie Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.6.5 AbbVie Inc. Recent Developments
11.7 GSK plc
11.7.1 GSK plc Corporation Information
11.7.2 GSK plc Business Overview
11.7.3 GSK plc Antibody-drug Conjugates Product Features and Attributes
11.7.4 GSK plc Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.7.5 GSK plc Recent Developments
11.8 ADC Therapeutics SA
11.8.1 ADC Therapeutics SA Corporation Information
11.8.2 ADC Therapeutics SA Business Overview
11.8.3 ADC Therapeutics SA Antibody-drug Conjugates Product Features and Attributes
11.8.4 ADC Therapeutics SA Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.8.5 ADC Therapeutics SA Recent Developments
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Corporation Information
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product Features and Attributes
11.9.4 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.9.5 Takeda Pharmaceutical Company Limited Recent Developments
11.10 AstraZeneca plc
11.10.1 AstraZeneca plc Corporation Information
11.10.2 AstraZeneca plc Business Overview
11.10.3 AstraZeneca plc Antibody-drug Conjugates Product Features and Attributes
11.10.4 AstraZeneca plc Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Genmab A/S
11.11.1 Genmab A/S Corporation Information
11.11.2 Genmab A/S Business Overview
11.11.3 Genmab A/S Antibody-drug Conjugates Product Features and Attributes
11.11.4 Genmab A/S Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.11.5 Genmab A/S Recent Developments
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Corporation Information
11.12.2 Johnson & Johnson Business Overview
11.12.3 Johnson & Johnson Antibody-drug Conjugates Product Features and Attributes
11.12.4 Johnson & Johnson Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.12.5 Johnson & Johnson Recent Developments
11.13 Merck & Co., Inc.
11.13.1 Merck & Co., Inc. Corporation Information
11.13.2 Merck & Co., Inc. Business Overview
11.13.3 Merck & Co., Inc. Antibody-drug Conjugates Product Features and Attributes
11.13.4 Merck & Co., Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.13.5 Merck & Co., Inc. Recent Developments
11.14 MacroGenics, Inc.
11.14.1 MacroGenics, Inc. Corporation Information
11.14.2 MacroGenics, Inc. Business Overview
11.14.3 MacroGenics, Inc. Antibody-drug Conjugates Product Features and Attributes
11.14.4 MacroGenics, Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.14.5 MacroGenics, Inc. Recent Developments
11.15 Sutro Biopharma, Inc.
11.15.1 Sutro Biopharma, Inc. Corporation Information
11.15.2 Sutro Biopharma, Inc. Business Overview
11.15.3 Sutro Biopharma, Inc. Antibody-drug Conjugates Product Features and Attributes
11.15.4 Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.15.5 Sutro Biopharma, Inc. Recent Developments
11.16 Heidelberg Pharma AG
11.16.1 Heidelberg Pharma AG Corporation Information
11.16.2 Heidelberg Pharma AG Business Overview
11.16.3 Heidelberg Pharma AG Antibody-drug Conjugates Product Features and Attributes
11.16.4 Heidelberg Pharma AG Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.16.5 Heidelberg Pharma AG Recent Developments
11.17 RemeGen Co., Ltd.
11.17.1 RemeGen Co., Ltd. Corporation Information
11.17.2 RemeGen Co., Ltd. Business Overview
11.17.3 RemeGen Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.17.4 RemeGen Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.17.5 RemeGen Co., Ltd. Recent Developments
11.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
11.18.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Corporation Information
11.18.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Business Overview
11.18.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.18.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.18.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
11.19 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.19.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Corporation Information
11.19.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
11.19.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.19.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.19.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
11.20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
11.20.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Corporation Information
11.20.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview
11.20.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.20.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.20.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments
11.21 Innovent Biologics, Inc.
11.21.1 Innovent Biologics, Inc. Corporation Information
11.21.2 Innovent Biologics, Inc. Business Overview
11.21.3 Innovent Biologics, Inc. Antibody-drug Conjugates Product Features and Attributes
11.21.4 Innovent Biologics, Inc. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.21.5 Innovent Biologics, Inc. Recent Developments
11.22 CSPC Pharmaceutical Group Limited
11.22.1 CSPC Pharmaceutical Group Limited Corporation Information
11.22.2 CSPC Pharmaceutical Group Limited Business Overview
11.22.3 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product Features and Attributes
11.22.4 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.22.5 CSPC Pharmaceutical Group Limited Recent Developments
11.23 Mabwell (Shanghai) Bioscience Co., Ltd.
11.23.1 Mabwell (Shanghai) Bioscience Co., Ltd. Corporation Information
11.23.2 Mabwell (Shanghai) Bioscience Co., Ltd. Business Overview
11.23.3 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.23.4 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.23.5 Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments
11.24 Lepu Biopharma Co., Ltd.
11.24.1 Lepu Biopharma Co., Ltd. Corporation Information
11.24.2 Lepu Biopharma Co., Ltd. Business Overview
11.24.3 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.24.4 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.24.5 Lepu Biopharma Co., Ltd. Recent Developments
11.25 Duality Biologics (Shanghai) Co., Ltd.
11.25.1 Duality Biologics (Shanghai) Co., Ltd. Corporation Information
11.25.2 Duality Biologics (Shanghai) Co., Ltd. Business Overview
11.25.3 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.25.4 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.25.5 Duality Biologics (Shanghai) Co., Ltd. Recent Developments
11.26 MediLink Therapeutics (Suzhou) Co., Ltd.
11.26.1 MediLink Therapeutics (Suzhou) Co., Ltd. Corporation Information
11.26.2 MediLink Therapeutics (Suzhou) Co., Ltd. Business Overview
11.26.3 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.26.4 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.26.5 MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments
11.27 GeneQuantum Healthcare (Suzhou) Co., Ltd.
11.27.1 GeneQuantum Healthcare (Suzhou) Co., Ltd. Corporation Information
11.27.2 GeneQuantum Healthcare (Suzhou) Co., Ltd. Business Overview
11.27.3 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.27.4 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.27.5 GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments
11.28 Hangzhou DAC Biotechnology Co., Ltd.
11.28.1 Hangzhou DAC Biotechnology Co., Ltd. Corporation Information
11.28.2 Hangzhou DAC Biotechnology Co., Ltd. Business Overview
11.28.3 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.28.4 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.28.5 Hangzhou DAC Biotechnology Co., Ltd. Recent Developments
11.29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
11.29.1 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Corporation Information
11.29.2 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Business Overview
11.29.3 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.29.4 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.29.5 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments
11.30 Sichuan Biokin Pharmaceutical Co., Ltd.
11.30.1 Sichuan Biokin Pharmaceutical Co., Ltd. Corporation Information
11.30.2 Sichuan Biokin Pharmaceutical Co., Ltd. Business Overview
11.30.3 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product Features and Attributes
11.30.4 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.30.5 Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments
11.31 Bio-Thera Solutions, Ltd.
11.31.1 Bio-Thera Solutions, Ltd. Corporation Information
11.31.2 Bio-Thera Solutions, Ltd. Business Overview
11.31.3 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product Features and Attributes
11.31.4 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue and Gross Margin (2021-2026)
11.31.5 Bio-Thera Solutions, Ltd. Recent Developments
12 Antibody-drug Conjugates Value Chain and Ecosystem Analysis
12.1 Antibody-drug Conjugates Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Antibody-drug Conjugates Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Antibody-drug Conjugates Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Antibody-drug Conjugates Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Antibody-drug Conjugates Market Size Growth Rate by Payload Mechanism, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Antibody-drug Conjugates Market Size Growth Rate by Drug-To-Antibody Ratio, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Antibody-drug Conjugates Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Antibody-drug Conjugates Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Antibody-drug Conjugates Revenue by Region (US$ Million), 2021-2026
Table 7. Global Antibody-drug Conjugates Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Antibody-drug Conjugates Revenue by Players (US$ Million), 2021-2026
Table 10. Global Antibody-drug Conjugates Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Antibody-drug Conjugates Revenue, 2025
Table 13. Global Antibody-drug Conjugates Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Antibody-drug Conjugates Companies Headquarters
Table 15. Global Antibody-drug Conjugates Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Antibody-drug Conjugates Revenue by Type (US$ Million), 2021-2026
Table 19. Global Antibody-drug Conjugates Revenue by Type (US$ Million), 2027-2032
Table 20. Global Antibody-drug Conjugates Revenue by Payload Mechanism (US$ Million), 2021-2026
Table 21. Global Antibody-drug Conjugates Revenue by Payload Mechanism (US$ Million), 2027-2032
Table 22. Global Antibody-drug Conjugates Revenue by Drug-To-Antibody Ratio (US$ Million), 2021-2026
Table 23. Global Antibody-drug Conjugates Revenue by Drug-To-Antibody Ratio (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Antibody-drug Conjugates Revenue by Application (US$ Million), 2021-2026
Table 26. Global Antibody-drug Conjugates Revenue by Application (US$ Million), 2027-2032
Table 27. Antibody-drug Conjugates High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Antibody-drug Conjugates Growth Accelerators and Market Barriers
Table 31. North America Antibody-drug Conjugates Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Antibody-drug Conjugates Growth Accelerators and Market Barriers
Table 33. Europe Antibody-drug Conjugates Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Antibody-drug Conjugates Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Antibody-drug Conjugates Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Antibody-drug Conjugates Investment Opportunities and Key Challenges
Table 37. Central and South America Antibody-drug Conjugates Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Antibody-drug Conjugates Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Antibody-drug Conjugates Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Daiichi Sankyo Company, Limited Corporation Information
Table 41. Daiichi Sankyo Company, Limited Description and Major Businesses
Table 42. Daiichi Sankyo Company, Limited Product Features and Attributes
Table 43. Daiichi Sankyo Company, Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Daiichi Sankyo Company, Limited Revenue Proportion by Product in 2025
Table 45. Daiichi Sankyo Company, Limited Revenue Proportion by Application in 2025
Table 46. Daiichi Sankyo Company, Limited Revenue Proportion by Geographic Area in 2025
Table 47. Daiichi Sankyo Company, Limited Antibody-drug Conjugates SWOT Analysis
Table 48. Daiichi Sankyo Company, Limited Recent Developments
Table 49. Roche Corporation Information
Table 50. Roche Description and Major Businesses
Table 51. Roche Product Features and Attributes
Table 52. Roche Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Roche Revenue Proportion by Product in 2025
Table 54. Roche Revenue Proportion by Application in 2025
Table 55. Roche Revenue Proportion by Geographic Area in 2025
Table 56. Roche Antibody-drug Conjugates SWOT Analysis
Table 57. Roche Recent Developments
Table 58. Pfizer Inc. Corporation Information
Table 59. Pfizer Inc. Description and Major Businesses
Table 60. Pfizer Inc. Product Features and Attributes
Table 61. Pfizer Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Pfizer Inc. Revenue Proportion by Product in 2025
Table 63. Pfizer Inc. Revenue Proportion by Application in 2025
Table 64. Pfizer Inc. Revenue Proportion by Geographic Area in 2025
Table 65. Pfizer Inc. Antibody-drug Conjugates SWOT Analysis
Table 66. Pfizer Inc. Recent Developments
Table 67. Gilead Sciences, Inc. Corporation Information
Table 68. Gilead Sciences, Inc. Description and Major Businesses
Table 69. Gilead Sciences, Inc. Product Features and Attributes
Table 70. Gilead Sciences, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Gilead Sciences, Inc. Revenue Proportion by Product in 2025
Table 72. Gilead Sciences, Inc. Revenue Proportion by Application in 2025
Table 73. Gilead Sciences, Inc. Revenue Proportion by Geographic Area in 2025
Table 74. Gilead Sciences, Inc. Antibody-drug Conjugates SWOT Analysis
Table 75. Gilead Sciences, Inc. Recent Developments
Table 76. Astellas Pharma Inc. Corporation Information
Table 77. Astellas Pharma Inc. Description and Major Businesses
Table 78. Astellas Pharma Inc. Product Features and Attributes
Table 79. Astellas Pharma Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Astellas Pharma Inc. Revenue Proportion by Product in 2025
Table 81. Astellas Pharma Inc. Revenue Proportion by Application in 2025
Table 82. Astellas Pharma Inc. Revenue Proportion by Geographic Area in 2025
Table 83. Astellas Pharma Inc. Antibody-drug Conjugates SWOT Analysis
Table 84. Astellas Pharma Inc. Recent Developments
Table 85. AbbVie Inc. Corporation Information
Table 86. AbbVie Inc. Description and Major Businesses
Table 87. AbbVie Inc. Product Features and Attributes
Table 88. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. AbbVie Inc. Recent Developments
Table 90. GSK plc Corporation Information
Table 91. GSK plc Description and Major Businesses
Table 92. GSK plc Product Features and Attributes
Table 93. GSK plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. GSK plc Recent Developments
Table 95. ADC Therapeutics SA Corporation Information
Table 96. ADC Therapeutics SA Description and Major Businesses
Table 97. ADC Therapeutics SA Product Features and Attributes
Table 98. ADC Therapeutics SA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. ADC Therapeutics SA Recent Developments
Table 100. Takeda Pharmaceutical Company Limited Corporation Information
Table 101. Takeda Pharmaceutical Company Limited Description and Major Businesses
Table 102. Takeda Pharmaceutical Company Limited Product Features and Attributes
Table 103. Takeda Pharmaceutical Company Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Takeda Pharmaceutical Company Limited Recent Developments
Table 105. AstraZeneca plc Corporation Information
Table 106. AstraZeneca plc Description and Major Businesses
Table 107. AstraZeneca plc Product Features and Attributes
Table 108. AstraZeneca plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. AstraZeneca plc Recent Developments
Table 110. Genmab A/S Corporation Information
Table 111. Genmab A/S Description and Major Businesses
Table 112. Genmab A/S Product Features and Attributes
Table 113. Genmab A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Genmab A/S Recent Developments
Table 115. Johnson & Johnson Corporation Information
Table 116. Johnson & Johnson Description and Major Businesses
Table 117. Johnson & Johnson Product Features and Attributes
Table 118. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Johnson & Johnson Recent Developments
Table 120. Merck & Co., Inc. Corporation Information
Table 121. Merck & Co., Inc. Description and Major Businesses
Table 122. Merck & Co., Inc. Product Features and Attributes
Table 123. Merck & Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Merck & Co., Inc. Recent Developments
Table 125. MacroGenics, Inc. Corporation Information
Table 126. MacroGenics, Inc. Description and Major Businesses
Table 127. MacroGenics, Inc. Product Features and Attributes
Table 128. MacroGenics, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. MacroGenics, Inc. Recent Developments
Table 130. Sutro Biopharma, Inc. Corporation Information
Table 131. Sutro Biopharma, Inc. Description and Major Businesses
Table 132. Sutro Biopharma, Inc. Product Features and Attributes
Table 133. Sutro Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Sutro Biopharma, Inc. Recent Developments
Table 135. Heidelberg Pharma AG Corporation Information
Table 136. Heidelberg Pharma AG Description and Major Businesses
Table 137. Heidelberg Pharma AG Product Features and Attributes
Table 138. Heidelberg Pharma AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Heidelberg Pharma AG Recent Developments
Table 140. RemeGen Co., Ltd. Corporation Information
Table 141. RemeGen Co., Ltd. Description and Major Businesses
Table 142. RemeGen Co., Ltd. Product Features and Attributes
Table 143. RemeGen Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. RemeGen Co., Ltd. Recent Developments
Table 145. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Corporation Information
Table 146. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 147. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Product Features and Attributes
Table 148. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
Table 150. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Corporation Information
Table 151. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 152. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 153. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
Table 155. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Corporation Information
Table 156. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Description and Major Businesses
Table 157. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Product Features and Attributes
Table 158. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments
Table 160. Innovent Biologics, Inc. Corporation Information
Table 161. Innovent Biologics, Inc. Description and Major Businesses
Table 162. Innovent Biologics, Inc. Product Features and Attributes
Table 163. Innovent Biologics, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Innovent Biologics, Inc. Recent Developments
Table 165. CSPC Pharmaceutical Group Limited Corporation Information
Table 166. CSPC Pharmaceutical Group Limited Description and Major Businesses
Table 167. CSPC Pharmaceutical Group Limited Product Features and Attributes
Table 168. CSPC Pharmaceutical Group Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. CSPC Pharmaceutical Group Limited Recent Developments
Table 170. Mabwell (Shanghai) Bioscience Co., Ltd. Corporation Information
Table 171. Mabwell (Shanghai) Bioscience Co., Ltd. Description and Major Businesses
Table 172. Mabwell (Shanghai) Bioscience Co., Ltd. Product Features and Attributes
Table 173. Mabwell (Shanghai) Bioscience Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments
Table 175. Lepu Biopharma Co., Ltd. Corporation Information
Table 176. Lepu Biopharma Co., Ltd. Description and Major Businesses
Table 177. Lepu Biopharma Co., Ltd. Product Features and Attributes
Table 178. Lepu Biopharma Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Lepu Biopharma Co., Ltd. Recent Developments
Table 180. Duality Biologics (Shanghai) Co., Ltd. Corporation Information
Table 181. Duality Biologics (Shanghai) Co., Ltd. Description and Major Businesses
Table 182. Duality Biologics (Shanghai) Co., Ltd. Product Features and Attributes
Table 183. Duality Biologics (Shanghai) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Duality Biologics (Shanghai) Co., Ltd. Recent Developments
Table 185. MediLink Therapeutics (Suzhou) Co., Ltd. Corporation Information
Table 186. MediLink Therapeutics (Suzhou) Co., Ltd. Description and Major Businesses
Table 187. MediLink Therapeutics (Suzhou) Co., Ltd. Product Features and Attributes
Table 188. MediLink Therapeutics (Suzhou) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments
Table 190. GeneQuantum Healthcare (Suzhou) Co., Ltd. Corporation Information
Table 191. GeneQuantum Healthcare (Suzhou) Co., Ltd. Description and Major Businesses
Table 192. GeneQuantum Healthcare (Suzhou) Co., Ltd. Product Features and Attributes
Table 193. GeneQuantum Healthcare (Suzhou) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments
Table 195. Hangzhou DAC Biotechnology Co., Ltd. Corporation Information
Table 196. Hangzhou DAC Biotechnology Co., Ltd. Description and Major Businesses
Table 197. Hangzhou DAC Biotechnology Co., Ltd. Product Features and Attributes
Table 198. Hangzhou DAC Biotechnology Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Hangzhou DAC Biotechnology Co., Ltd. Recent Developments
Table 200. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Corporation Information
Table 201. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Description and Major Businesses
Table 202. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Product Features and Attributes
Table 203. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments
Table 205. Sichuan Biokin Pharmaceutical Co., Ltd. Corporation Information
Table 206. Sichuan Biokin Pharmaceutical Co., Ltd. Description and Major Businesses
Table 207. Sichuan Biokin Pharmaceutical Co., Ltd. Product Features and Attributes
Table 208. Sichuan Biokin Pharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments
Table 210. Bio-Thera Solutions, Ltd. Corporation Information
Table 211. Bio-Thera Solutions, Ltd. Description and Major Businesses
Table 212. Bio-Thera Solutions, Ltd. Product Features and Attributes
Table 213. Bio-Thera Solutions, Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Bio-Thera Solutions, Ltd. Recent Developments
Table 215. Technologies, Platforms and Infrastructure
Table 216. Distributors List
Table 217. Market Trends and Market Evolution
Table 218. Market Drivers and Opportunities
Table 219. Market Challenges, Risks, and Restraints
Table 220. Research Programs/Design for This Report
Table 221. Key Data Information from Secondary Sources
Table 222. Key Data Information from Primary Sources


List of Figures
Figure 1. Global Antibody-drug Conjugates Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. HER2-Directed ADCs Product Picture
Figure 3. TROP2-Directed ADCs Product Picture
Figure 4. Hematologic-Lineage Antigen ADCs Product Picture
Figure 5. Other Target Antigen ADCs Product Picture
Figure 6. Global Antibody-drug Conjugates Market Size Growth Rate by Payload Mechanism, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Topoisomerase I Inhibitor ADCs Product Picture
Figure 8. Microtubule Inhibitor ADCs Product Picture
Figure 9. DNA-Damaging ADCs Product Picture
Figure 10. Other Payload ADCs Product Picture
Figure 11. Global Antibody-drug Conjugates Market Size Growth Rate by Drug-To-Antibody Ratio, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. DAR Up To 4 Product Picture
Figure 13. DAR Above 4 And Below 8 Product Picture
Figure 14. DAR 8 And Above Product Picture
Figure 15. Other Product Picture
Figure 16. Global Antibody-drug Conjugates Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 17. Breast and Gynecologic Malignancies
Figure 18. Lung and Other Thoracic Malignancies
Figure 19. Other Solid Tumors
Figure 20. Hematologic Malignancies
Figure 21. Antibody-drug Conjugates Report Years Considered
Figure 22. Global Antibody-drug Conjugates Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 24. Global Antibody-drug Conjugates Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 25. Global Antibody-drug Conjugates Revenue-Based Market Share by Region (2021-2032)
Figure 26. Global Antibody-drug Conjugates Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. HER2-Directed ADCs Revenue-Based Market Share by Player in 2025
Figure 29. TROP2-Directed ADCs Revenue-Based Market Share by Player in 2025
Figure 30. Hematologic-Lineage Antigen ADCs Revenue-Based Market Share by Player in 2025
Figure 31. Other Target Antigen ADCs Revenue-Based Market Share by Player in 2025
Figure 32. Global Antibody-drug Conjugates Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Antibody-drug Conjugates Revenue-Based Market Share by Payload Mechanism (2021-2032)
Figure 34. Global Antibody-drug Conjugates Revenue-Based Market Share by Drug-To-Antibody Ratio (2021-2032)
Figure 35. Global Antibody-drug Conjugates Revenue-Based Market Share by Application (2021-2032)
Figure 36. North America Antibody-drug Conjugates Revenue YoY (US$ Million), 2021-2032
Figure 37. North America Top 5 Players Antibody-drug Conjugates Revenue (US$ Million) in 2025
Figure 38. North America Antibody-drug Conjugates Revenue (US$ Million) by Application (2021-2032)
Figure 39. US Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 40. Canada Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 41. Mexico Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 42. Europe Antibody-drug Conjugates Revenue YoY (US$ Million), 2021-2032
Figure 43. Europe Top 5 Players Antibody-drug Conjugates Revenue (US$ Million) in 2025
Figure 44. Europe Antibody-drug Conjugates Revenue (US$ Million) by Application (2021-2032)
Figure 45. Germany Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 46. France Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 47. U.K. Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 48. Italy Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 49. Russia Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 50. Asia-Pacific Antibody-drug Conjugates Revenue YoY (US$ Million), 2021-2032
Figure 51. Asia-Pacific Top 8 Players Antibody-drug Conjugates Revenue (US$ Million) in 2025
Figure 52. Asia-Pacific Antibody-drug Conjugates Revenue (US$ Million) by Application (2021-2032)
Figure 53. Indonesia Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 54. Japan Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 55. South Korea Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 56. Australia Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 57. India Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 58. Indonesia Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 59. Vietnam Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 60. Malaysia Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 61. Philippines Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 62. Singapore Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 63. Central and South America Antibody-drug Conjugates Revenue YoY (US$ Million), 2021-2032
Figure 64. Central and South America Top 5 Players Antibody-drug Conjugates Revenue (US$ Million) in 2025
Figure 65. Central and South America Antibody-drug Conjugates Revenue (US$ Million) by Application (2021-2032)
Figure 66. Brazil Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 67. Argentina Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 68. Middle East and Africa Antibody-drug Conjugates Revenue YoY (US$ Million), 2021-2032
Figure 69. Middle East and Africa Top 5 Players Antibody-drug Conjugates Revenue (US$ Million) in 2025
Figure 70. Middle East and Africa Antibody-drug Conjugates Revenue (US$ Million) by Application (2021-2032)
Figure 71. GCC Countries Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 72. Israel Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 73. Egypt Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 74. South Africa Antibody-drug Conjugates Revenue (US$ Million), 2021-2032
Figure 75. Antibody-drug Conjugates Value Chain Mapping
Figure 76. Channels of Distribution (Direct Vs Distribution)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed